The 2022 Tandem Meetings | Choosing between tisa-cel, liso-cel & axi-cel in LBCL
Craig W. Freyer, PharmD, BCOP, Hospital of the University of Pennsylvania, Philadelphia, PA, comments on the difficulty to compare and choose between the three FDA approved CAR-T products in large B-cell lymphoma (LBCL), axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), and tisagenlecleucel (tisa-cel). Due to significant differences between the clinical trials that evaluated these CAR-T therapies, it is difficult to compare these products. Nevertheless, Dr Freyer explains that axi-cel is often the drug of choice in young patients with a good performance status as it appears to induce better responses. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
